Display search results for ** instead (7 products)
02 Nov 2016  |  Global
This Vital Signs issue discusses the Danaher's acquisition of Cepheid for nearly $4 Billion in cash, and Orphan Drug Expenditures in the United States: A Historical and Prospective Analysis, 2007–2013.
USD 450.00 save 25 %
26 Sep 2016  |  Global
2015 was the year for Internet of Things (IoT) in term of positive perspectives, growth potential, industry impacts, and new revenue sources. Frost & Sullivan revealed that by 2020, the total global market will reach over $200 billion and every household will have at least 10 connected devices. In the coming year, the construction market will emerg...
USD 375.00 save 25 %
30 Aug 2016  |  Global
This Vital Signs issue discusses the clinical diagnostics laboratory tests payment system, approval of a Zika test kit, the impact on innovation of mergers in the pharma/biotech industry, and national healthcare expenditure projections through 2025.
USD 450.00 save 25 %
02 Aug 2016  |  Global
This Vital Signs issue discusses Luminex's acquisition of Nanosphere, Medicare's changing approach to paying doctors, Orig3N's partnership with the San Francisco 49ers for collection of blood samples for research, and FDA's halt of Juno Therapeuticss cell therapy trial which left three dead.
30 Jun 2016  |  Global
This Vital Signs issue discusses Sinocare's acquisition of PTS Diagnostics, biosimilar drug pricing, Americans' usage of prescription pain killers, and Takara Bio's acquistion of Wafergen Bio-systems.
24 May 2016  |  Global
This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.
04 Apr 2016  |  Global
Exciting Developments in Generic Drug Pricing, CRISPR Technology, GenomeAsia 100K and Large-scale Next-generation Sequencing Projects, and Medicare Outcomes
This Vital Signs issues discusses generic drug pricing, CRISPR technology, GenomeAsia 100K and large-scale next-generation sequencing projects, and Medicare outcomes target.